SNY vs SYRE: Which Is the Better Buy in 2026?
Last updated August 2026
Short answer
SNY is the larger of the two ($103.23B market cap): the incumbent the market prices for continued execution (8.34x forward earnings, beta 0.28). SYRE is the smaller challenger ($8.54B), priced similarly on forward earnings (-31.43x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
SNY vs SYRE: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | SNY | SYRE | What it tells you |
|---|---|---|---|
| Market cap | $103.23B | $8.54B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 8.34 | -31.43 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.28 | 3.02 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 19% of range | 93% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
Before you buy: how SNY and SYRE affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. SNY and SYRE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined SNY and SYRE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Sanofi (SNY) do?
Sanofi S.A. is one of the world's largest pharmaceutical companies, based in France and organized around biopharma (specialty care, general medicines) and vaccines. Its single most important product is Dupixent, an immunology drug co-developed with Regeneron that treats conditions like eczema, asthma, and COPD; Dupixent sales moved above the roughly four-billion-euro-per-quarter mark in Q1 2026 and grew more than 30% year over year, making it the engine of the company's revenue growth. Sanofi also runs a major vaccines business (including the RSV antibody Beyfortus and the newly acquired hepatitis-B vaccine Heplisav-B) and spun off its consumer-health arm, Opella (Allegra, Icy Hot, Dulcolax), in 2025 to focus purely on innovative medicines and vaccines.
What does Spyre Therapeutics (SYRE) do?
Spyre Therapeutics (Nasdaq: SYRE) is a clinical-stage biotechnology company building extended half-life antibodies and antibody combinations aimed at inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, plus rheumatic diseases. Its lead programs target the TL1A pathway (SPY002 and SPY072) and complementary mechanisms such as alpha4beta7 (SPY001) and IL-23 (SPY003), engineered for less frequent dosing (potentially quarterly or twice-yearly) than existing biologics like Entyvio. The company has no marketed products and generates no product revenue; its worth is tied to clinical progress and the large addressable IBD market.
SNY vs SYRE: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- SNY drivers: Dupixent as the growth engine; Pipeline and new launches.
- SYRE drivers: TL1A pipeline and 2026 catalyst cadence; Differentiated long-acting dosing.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The clearest risk is concentration in Dupixent: with one product carrying so much of the growth, its eventual loss of patent exclusivity later this decade is the central overhang, and the pipeline may or may not fully replace it. For SYRE, spyre is pre-revenue and unprofitable, with a net loss of roughly $149 million over the trailing twelve months (as of July 2026), so the valuation rests entirely on future clinical success.
SNY or SYRE: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick SNY if you believe its drivers more; SYRE if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the SNY and SYRE guides.
SNY vs SYRE: the full fundamentals
SNY. Figures are approximate, drawn from public 2026 reporting, and tied to the asOf date; verify live numbers before acting. Sanofi reports in euros, so the dollar value of SNY and its dividend also depends on the euro-to-dollar exchange rate. As a defensive large-cap pharma, the stock tends to trade on pipeline news, Dupixent momentum, and the eventual patent-expiry timeline rather than on sharp cyclical swings.
SYRE. Spyre has no product revenue and posts steady losses funding R&D, so traditional earnings and valuation multiples do not apply (as of July 2026). Its roughly $8.2 billion market cap reflects expectations for its TL1A and IBD pipeline, not current cash flow. Investors weigh cash runway against clinical milestones rather than profits.
Headline figures (approximate, Jul 2026): SNY shows company type Large-cap, diversified global pharmaceutical company (French, US-listed as an ADR on Nasdaq), market cap ~$107 billion (approximate; among the larger global pharma names), q1 2026 revenue ~10.5 billion euros, ahead of consensus (reported figures are in euros), q1 2026 business eps ~1.88 euros, up ~14% at constant exchange rates; SYRE shows product revenue (ttm) ~$0 (clinical-stage), net loss (ttm) ~-$149M, eps (ttm) ~-$2.17, cash and investments ~$780M (runway into late 2028).
The bottom line: SNY vs SYRE
SNY and SYRE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined SNY and SYRE exposure against your real portfolio. It is not an investment adviser.
Wondering how SNY or SYRE fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Sanofi with AI
Connect the broker you already use and ask Walnut's AI how SNY fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between SNY and SYRE?
+
Sanofi S.A. Spyre Therapeutics (Nasdaq: SYRE) is a clinical-stage biotechnology company building extended half-life antibodies and antibody combinations aimed at inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, plus rheumatic diseases. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is SNY or SYRE the better stock?
+
Neither is universally better. SNY is the larger incumbent; SYRE is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, SNY or SYRE?
+
On forward P/E (as of August 2026), SNY trades at 8.34x and SYRE at -31.43x, so SYRE is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both SNY and SYRE?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of SNY vs SYRE?
+
SNY: The clearest risk is concentration in Dupixent: with one product carrying so much of the growth, its eventual loss of patent exclusivity later this decade is the central overhang, and the pipeline may or may not fully replace it. Drug development is inherently uncertain, as the December 2025 US complete response letter for tolebrutinib in non-relapsing secondary progressive MS showed, even as the EU approved it. Because SNY is an ADR of a euro-reporting company, currency swings between the euro and dollar affect reported results and the dollar value of the dividend, adding volatility unrelated to the business. Pharma also faces pricing pressure, US drug-pricing policy, patent litigation, and competition from large rivals and biosimilars. Vaccine demand is seasonal and competitive, as Beyfortus experienced in the US market. SYRE: Spyre is pre-revenue and unprofitable, with a net loss of roughly $149 million over the trailing twelve months (as of July 2026), so the valuation rests entirely on future clinical success. Its programs are mostly early to mid-stage, and Phase 2 results do not guarantee Phase 3 or approval; a single failed readout among the six planned for 2026 could sharply cut the stock. The TL1A space is intensely competitive, with Merck's tulisokibart already reporting pivotal ulcerative colitis data and Roche, Sanofi/Teva, and others racing ahead, meaning Spyre may reach market later than established rivals. The stock is highly volatile (beta near 3), and further equity raises would dilute holders. Any clinical, regulatory, or safety setback carries outsized downside for a company with no product sales.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell SNY or SYRE; figures are approximate and dated (as of August 2026). Verify current data before investing.